Every 8-K that GRAIL, Inc. (GRAL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GRAL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRAL filings page.
GRAIL, Inc. reported solid growth for the quarter ended June 30, 2026, with total revenue up 26% year-over-year to $44.7 million. Galleri screening revenue rose 24% to $42.6 million as Galleri test volume increased 35% to more than 61,000 tests. For the first half of 2026, Galleri revenue grew 30% to $82.5 million on test volume growth of 42% to more than 117,000.
The company recorded a net loss of $110.2 million, an improvement of 3% versus the prior-year quarter, and a gross loss of $12.6 million. Non-GAAP metrics showed adjusted gross profit of $21.6 million and adjusted EBITDA of $(90.3) million. Cash, cash equivalents, and short-term marketable securities totaled $861.6 million as of June 30, 2026.
GRAIL highlighted positive clinical data from the large NHS-Galleri and PATHFINDER 2 multi-cancer early detection studies and completed a $110 million equity financing with Samsung, with plans to commercialize Galleri in South Korea and potentially other Asian markets. The company anticipates an FDA advisory committee in the fall to review its Premarket Approval application for the Galleri test.
GRAIL, Inc. held its Annual Meeting of Stockholders on June 18, 2026, with a quorum of 35,076,394 shares present out of 42,916,593 shares entitled to vote as of the April 22, 2026 record date.
Stockholders elected Class II directors Sarah Krevans and Steven Mizell to serve until the 2029 annual meeting. Krevans received 18,929,398 votes for and 2,972,804 withheld, while Mizell received 16,998,081 votes for and 4,904,121 withheld, in each case with 13,174,192 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,611,318 votes for, 57,682 against, and 407,394 abstentions.
GRAIL, Inc. updated the employment terms for its new Chief Executive Officer, Dr. Joshua Ofman, and showcased detailed clinical data for its Galleri multi‑cancer early detection test. The amended offer letter makes Dr. Ofman the principal executive officer as of June 1, 2026, with an annual base salary of $800,000 and a variable compensation plan target equal to 100% of salary from that date. He will receive restricted stock units valued at $2,000,000, vesting over four years, and significant severance protections, including up to 24 months of salary, 200% of target bonus, full equity acceleration, and extended healthcare benefits if he is terminated without cause or resigns for good reason in connection with a change in control.
The accompanying investor presentation from ASCO 2026 highlights results from the NHS‑Galleri and PATHFINDER 2 trials, covering roughly 180,000 participants. Adding Galleri to standard screening reduced Stage IV cancers for 12 deadly cancer types by more than 20% in incident screening rounds, increased early‑stage (Stage I/II) detections by about 16%, and quadrupled screening‑detected cancers versus standard screening alone. The test showed positive predictive value around 52–60%, a false positive rate below 0.5%, and high accuracy in predicting cancer signal origin, with no serious study‑related adverse events reported.
GRAIL, Inc. reported strong first-quarter 2026 growth, with total revenue of $40.8 million, an increase of 28% year over year. Galleri test revenue reached $39.8 million, up 37%, as test volume grew 50% to more than 56,000 tests.
The company recorded a net loss of $93.2 million, an improvement of 12%, and a gross loss of $14.3 million. Non-GAAP adjusted gross profit was $19.7 million, while adjusted EBITDA was a loss of $79.9 million, a 19% improvement.
GRAIL ended the quarter with $823.1 million in cash, cash equivalents, and short-term marketable securities. The FDA accepted its Premarket Approval application for the Galleri test, and GRAIL plans to integrate Galleri into Epic’s electronic health record platform to broaden access.
GRAIL, Inc. reported strong 2025 growth while remaining deeply loss-making and released landmark trial data for its Galleri multi-cancer blood test. Full-year revenue rose 17% to $147.2 million, driven by 26% growth in U.S. Galleri revenue to $136.8 million and more than 185,000 tests sold. Fourth-quarter revenue grew 14% to $43.6 million. Net loss narrowed sharply to $408.4 million from $2.03 billion, largely because 2024 included a large goodwill and intangible impairment; adjusted EBITDA improved to $(320.6) million. Cash, cash equivalents and short-term marketable securities totaled $904.4 million, which the company says supports operations into 2030.
The randomized NHS-Galleri trial in England did not meet its primary endpoint of a statistically significant reduction in combined Stage III–IV cancers, but showed a substantial reduction in Stage IV diagnoses, higher Stage I–II detection and a four-fold higher cancer detection rate when Galleri was added to standard screening. GRAIL completed its Galleri premarket approval submission to the FDA, finished analysis of the 35,000-participant PATHFINDER 2 study, and highlighted a new U.S. Medicare coverage pathway for multi-cancer early detection tests. Based on NHS-Galleri and PATHFINDER 2 results, the company plans to expand its U.S. field sales and medical teams.
GRAIL, Inc. reported that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. The company states that the slide presentation to be used at the conference is being furnished as Exhibit 99.1 to this current report. The company clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, meaning it is not subject to certain liabilities under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless specifically referenced. The report is signed on behalf of GRAIL by its Chief Financial Officer, Aaron Freidin.
GRAIL, Inc. reported two capital markets updates. The company filed a prospectus supplement for the resale of 3,925,767 shares of common stock previously issued to selling stockholders, consisting of 1,927,194 shares and 1,998,573 shares issuable upon exercise of pre-funded warrants. These securities were issued under a securities purchase agreement dated October 18, 2025 and are covered by GRAIL’s Form S-3 shelf.
GRAIL also entered an Equity Distribution Agreement with Morgan Stanley and TD Securities to establish an at-the-market program allowing sales of up to $300,000,000 of common stock from time to time. Sales may be made in transactions permitted by Rule 415, with a commission of up to 3.0% of gross proceeds payable to the sales agents. Related legal opinions and the agreement were filed as exhibits.
GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement of 4,639,543 shares of common stock (or pre-funded warrants with a $0.001 exercise price) at $70.05 per share, for approximate gross proceeds of $325.0 million. Closing is expected on October 21, 2025.
The pre-funded warrants are immediately exercisable and include a Beneficial Ownership Limitation of 4.99% or 9.99% (holder election), which may be increased upon 61 days’ notice up to 19.99%. GRAIL agreed to file a resale registration statement within 30 days after closing and use reasonable best efforts to obtain effectiveness within 60 days of filing or within 5 business days after an SEC no-review notice. The transaction is exempt under Section 4(a)(2) and Regulation D.
GRAIL, Inc. agreed to a private placement with Samsung C&T and Samsung Electronics Singapore for 1,570,308 common shares at $70.05 per share, pursuant to a Stock Purchase Agreement. Closing is conditioned on regulatory clearances, including CFIUS, and execution by January 31, 2026 of a business collaboration with Samsung C&T for exclusive Galleri commercialization in Korea and a strategic collaboration with Samsung Electronics.
The company plans to use net proceeds for general corporate purposes to support commercialization and reimbursement efforts. GRAIL will file a resale registration covering the shares within 180 days after closing.
GRAIL also disclosed preliminary Q3 2025 results: US screening revenue between $32.1–$33.1 million, total revenue between $35.7–$36.7 million, and losses from operations between $123.9–$126.9 million. Cash, cash equivalents, restricted cash and short-term marketable securities were approximately $547 million as of September 30, 2025. These figures are preliminary and unaudited.
GRAIL, Inc. has signed a long-term lease for a new corporate headquarters at 250 S. Matilda Avenue in Sunnyvale, California. The company will lease approximately 75,556 rentable square feet from Sunnyvale Office Acquisition, LLC.
The lease is expected to begin on or about October 1, 2026 and run through on or about September 30, 2037. Initial base rent is approximately $449,558 per month, with about 5% annual increases, plus additional costs such as building expenses and taxes.
GRAIL has rights to expand into additional space and may renew the lease for an extra five-year term under specified conditions. The arrangement requires a letter of credit as security and includes customary covenants, representations, obligations and indemnities for both parties.
GRAIL, Inc. furnished a press release reporting its financial results for the second quarter ended June 30, 2025; the press release is attached as Exhibit 99.1 to this current report. The 8-K text states the press release announces second-quarter financial results but does not include the underlying financial tables or metrics within the filing itself.
The exhibit is furnished, not filed, so the press release is not automatically incorporated by reference into other SEC filings unless explicitly stated. The report also identifies the company as an emerging growth company and confirms its common stock (par value $0.001) trades under the symbol GRAL on the Nasdaq Global Select Market. Readers must consult Exhibit 99.1 for the full financial figures and management commentary.